A-269 Post-pandemic Opportunities for Commercial Laboratories in Infectious Disease Diagnostics and Public Health
D Nall,X Thacker,B Sengsouk,M Hardison,C Clark
DOI: https://doi.org/10.1093/clinchem/hvad097.237
IF: 12.114
2023-09-27
Clinical Chemistry
Abstract:Abstract Background Aegis launched COVID-19 testing with a daily capacity of 3000 tests and scaled to over 100 000 tests/day in one year. The lab has performed over 14.2M COVID-19 tests to date, servicing a broad network of physicians, urgent care centers, nursing homes, public schools, departments of health, and retail pharmacies across the United States. As SARS-CoV-2 infections reach an equilibrium, Aegis recognized the opportunity to address broader public health needs and leveraged the partnerships, technologies, and infrastructure developed to build the Infectious Disease Testing (IDT) menu aimed at limiting the spread of health risks within the community. Methods Real-time polymerase chain reaction (RT-PCR) tests for common and rare bacterial, viral, and parasitic pathogens associated with genital health (GH) and sexually transmitted infections (STI), as well as infections of the urinary (UTI), gastrointestinal (GI), and respiratory tracts (RTI) were validated. These tests are performed in 384-well custom PCR plates, pre-spotted with primers and probes capable of detecting the presence of DNA or RNA (LOD = 10 copies/μL) from 30 different organisms in up to 12 patient samples simultaneously. Syndromic panels were developed for ordering based on similar intended use, and providers have the option to order panels or stand-alone tests based on medical necessity. Following receipt into the lab, the total nucleic acid is extracted from the primary specimen and pipetted into the PCR assay plate with Taq DNA polymerase master mix, and analysis and reporting of ordered targets are complete within nine hours, on average. Results and de-identified demographic data are parsed from the laboratory information management system (LIMS) to Microsoft PowerBI software to internally track testing trends, positivity rates, and outbreaks of infectious diseases. Results Historical data including ordered profiles, matrices, and pathogens detected combined with de-identified demographic data such as patient age, gender, race, residing state, and collection month were imported into PowerBI and used to create interactive visuals for a dashboard to monitor trends and predict future testing patterns. The IDT panels ordered most frequently include STI (27.1%), upper RTI (23.6%), bacterial vaginosis (21.0%), GI bacterial (15.1%), candidiasis (13.7%), and GI viral (13.0%). The majority (74%) of GH/STI tests were ordered for patients between the ages of 15 to 34 years, and the most prevalent infections detected were bacterial vaginosis (35%), mycoplasma hominis (22%), and chlamydia trachomatis (4%). Sixty-one percent (61%) of upper RTI tests were ordered for patients between the ages of 0 to 14 years, and fluctuations in positivity rates followed seasonal trends for pathogens such as rhinovirus, influenza, adenovirus, RSV, and enterovirus D68. GI profiles were predominantly ordered for the younger (0–14 years, 35%) and the older (>65 years, 18%) population with e. coli O157 (11%), norovirus (9%), sapovirus (6%), and astrovirus (4%) infections detected at the highest rates. Conclusion The COVID-19 pandemic underscored the importance of molecular diagnostics for SARS-CoV-2 infection and surveillance. Experience gained during the COVID-19 response allowed Aegis to repurpose the resources, capacity, and infrastructure to create business development opportunities aimed at laboratory growth in infectious diseases and public health.
medical laboratory technology